SALES surged in the first quarter at drugs giant AstraZeneca on the back of its push into cancer drugs and emerging markets.
Revenues grew for the third consecutive quarter, with a 14 per cent increase in product sales to $5.5 billion (£4.2bn) after removing currency fluctuations.
In February, the FTSE 100 company reported annual sales growth for the first time since 2009, turning the business round after it was hampered by patent losses.
The turnaround has been driven by its growth in cancer drug sales, which soared 59% to $1.9bn (£1.5bn) and accounted for 35% of total product sales.
It is heavily investing in cancer treatment development to continue sales growth, and last month announced plans to pay up to $6.9bn (£5.3bn) to Japan's Daiichi Sankyo to develop and sell next-generation drugs.
Sales in Europe fell by 6%, while sales in the US jumped by 20%.
Profitability also improved as its operating margin rose 7 percentage points to 20%.
AstraZeneca said it is on track to hit its annual sales and earnings targets and has extensively prepared to deal with the impact of a disorderly exit from the EU.
Astrazeneca CEO Pascal Soriot said: "Our core operating profit almost doubled, demonstrating strong operating-margin improvement.
"Together with this encouraging financial start to the year, our highly-productive and sustainable pipeline continued to deliver."
Nicholas Hyett, equity analyst at Hargreaves Lansdown, said: "Pascal Soriot will be feeling a degree of vindication in these numbers. Revenue growth is no longer a matter of faith for Astra investors, it can be seen in black and white."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here